ReviewEndocrine-related cancer2014
Androgen biosynthesis in castration-resistant prostate cancer.
Review in Endocrine-related cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.Endocrine-related cancer · 2017Trial
- AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications.ACS medicinal chemistry letters · 2024Article
- Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.Journal of medicinal chemistry · 2023Article
- Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.The Journal of urology · 2022Article
- Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.Oncogene · 2021Review
- Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics.Trends in endocrinology and metabolism: TEM · 2020Review
- Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins.New journal of chemistry = Nouveau journal de chimie · 2020Article
- AR mRNA stability is increased with AR-antagonist resistance via 3'UTR variants.Endocrine connections · 2020Article
- Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope.Cancers · 2019Review
- Non-nuclear AR Signaling in Prostate Cancer.Frontiers in chemistry · 2019Review
- Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer.Asian journal of urology · 2019Review
- Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.Oncotarget · 2018Article
- Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Frontiers in oncology · 2018Review
- Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.The Journal of steroid biochemistry and molecular biology · 2017Article
- Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.Oncotarget · 2016Article
- Androgen receptor aberrations in the era of abiraterone and enzalutamide.World journal of urology · 2016Review
- Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.Oncotarget · 2016Article
- Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.Database : the journal of biological databases and curation · 2016Article
- A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.International journal of nanomedicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is the second leading cause of death in adult males in the USA. Recent advances have revealed that the fatal form of this cancer, known as castration-resistant prostate cancer (CRPC), remains hormonally driven despite castrate levels of circulating androgens. CRPC arises as the tumor undergoes adaptation to low levels of androgens by either synthesizing its own androgens (intratumoral androgens) or altering the androgen receptor (AR). This article reviews the major routes to testosterone and dihydrotestosterone synthesis in CRPC cells and examines the enzyme targets and progress in the development of isoform-specific inhibitors that could block intratumoral androgen biosynthesis. Because redundancy exists in these pathways, it is likely that inhibition of a single pathway will lead to upregulation of another so that drug resistance would be anticipated. Drugs that target multiple pathways or bifunctional agents that block intratumoral androgen biosynthesis and antagonize the AR offer the most promise. Optimal use of enzyme inhibitors or AR antagonists to ensure maximal benefits to CRPC patients will also require application of precision molecular medicine to determine whether a tumor in a particular patient will be responsive to these treatments either alone or in combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.